Methods and compositions for the treatment of ocular diseases

Abstract

Methods and compositions for the tretament of ocular disease with a cyclin dependent kinase inhibitor are provided.

What is claimed is:  
     
         1 . A method for the treatment of an ocular disease comprising the administration of a nucleotide sequence encoding a cyclin dependent kinase inhibitor.  
     
     
         2 . The method of  claim 1 , wherein the cyclin dependent kinase inhibitor is p16 or p21.  
     
     
         3 . The method of  claim 2 , wherein the cyclin dependent kinase inhibitor is p21.  
     
     
         4 . The method of  claim 3 , wherein p21 is provided in an viral vector.  
     
     
         5 . The method of  claim 4  wherein the viral vector is an adenoviral vector.  
     
     
         6 . The method of  claim 5  wherein the adenoviral vector is a human adenovirus type 5 vector.  
     
     
         7 . The method of  claim 6  wherein the human adenovirus vector is a replication deficient adenoviral vector.  
     
     
         8 . The method of  claim 7  wherein the replication deficient vector is deleted in the E4 region.  
     
     
         9 . The method of  claim 8  wherein the vector retains E4 orf 6 and E4 orf 6/7 but does not encode functional E4 peptide.  
     
     
         10 . The method of  claim 1  wherein the ocular disease is selected from the group consisting of glaucoma surgery failure, proliferative vitreoretinopathy and age related macular degeneration, retinopathy of prematurity, and diabetic retinopathy.  
     
     
         11 . The method of  claim 1  wherein the cyclin dependent kinase inhibitor is p21 or p16.  
     
     
         12 . The method of  claim 1 , wherein said cyclin dependent kinase inhibitor is p21.